CD34 and acute graft versus host disease: In a multivariate analysis, CD3+ dose was the only adverse predicting factor for acute GVHD grade II-IV (HR= 2.1; 95%CI: 1.25-3.55, P = .005) and together with CD34+ dose for acute GVHD grade III-IV (CD3+, HR=3.6; 95%CI: 1.45-9.96, P = .006; CD34+, HR=2.65; 95%CI: 1.07-6.57, P = .04).